Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.950
-1.210 (-19.64%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Elicio Therapeutics Employees
Elicio Therapeutics had 32 employees as of December 31, 2023. The number of employees increased by 9 or 39.13% compared to the previous year.
Employees
32
Change (1Y)
9
Growth (1Y)
39.13%
Revenue / Employee
n/a
Profits / Employee
-$1,621,813
Market Cap
78.44M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 32 | 9 | 39.13% |
Dec 31, 2022 | 23 | -1 | -4.17% |
Dec 31, 2021 | 24 | 2 | 9.09% |
Dec 31, 2020 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ELTX News
- 1 day ago - Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 8 days ago - Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewsWire
- 2 months ago - Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data - Seeking Alpha
- 2 months ago - Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 months ago - Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting - GlobeNewsWire
- 5 months ago - Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit - GlobeNewsWire